Merck & Co opened higher at $149.55, compared with its previous close of $146.33. In the last trading session, the stock traded between $147.40 and $151.35. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Merck & Co is now worth
$ 170.06
giving a profit of
$ 70.06 (70.06%)
Note: Past profits do not guarantee future returns.
Rating from 21 Analysts
Today's Change
+$3.40 (+2.33%)
Day High
$151.35
Day Low
$147.40
Day Open
$149.55
Prev Close
$146.33
Volume
43,25,781
1W Return
1.72%
1M Return
0.28%
3M Return
14.86%
6M Return
34.96%
1Y Return
72.94%
Market Cap ($ Mn)
3,69,420
PE Ratio
117.74
PB Ratio
8.73
PEG Ratio
8.72
ROE
36.81%
ROCE
23.02%
EPS (TTM)
$-0.54
1 Week
1.72%
1 Month
0.28%
3 Months
14.86%
6 Months
34.96%
9 Months
38.21%
Merck withdraws Zinplava from Europe after commercial review
Merck & Co Inc permanently discontinues Zinplava in Europe for commercial reasons. European Commission withdrew marketing authorization on Tuesday following holder request. The move follows the therapy's discontinuation in the United States in December 2024. Zinplava was approved for preventing recurrent Clostridium difficile infection.
10 days agoMerck & Co elects Paul J. Diaz to board effective Nov 2026
Paul J. Diaz joins Merck's board effective November 1, 2026. Board size increases to 14 members with this addition. Diaz stands for shareholder election in May 2027. He is managing partner at Cressey & Company.
17 days agoCitigroup raises Merck price target to $145, maintains neutral
Citigroup raises Merck & Co price target from $125 to $145. Analyst Geoff Meacham maintains a Neutral rating on the stock. The revised target represents a 16% increase over the previous level.
17 days agoMerck’s tulisokibart meets Phase 2b endpoints in skin therapy trial
Tulisokibart met primary endpoint HiSCR50 at week 16 in Phase 2b hidradenitis suppurativa trial. High-dose group achieved 72% response rate, a 37% improvement over placebo. Safety profile comparable to placebo with no serious opportunistic infections reported. Low-dose cohort showed clinical efficacy but no improvement in quality of life scores.
29 days agoMerck and Daiichi Sankyo withdraw FDA application for lung cancer drug
Merck and Daiichi Sankyo withdrew the BLA for ifinatamab deruxtecan after FDA feedback on accelerated approval criteria. Phase 2 trial showed a confirmed objective response rate of 48.2% in 137 patients with previously treated ES-SCLC. Median overall survival was 10.3 months, while median progression-free survival was 4.9 months. Merck entered a $2.13 billion potential value license agreement with SciBrunch Therapeutics for SPR2015. The upfront payment to SciBrunch is $400 million, resulting in a Q3FY26 pre-tax charge for Merck.
1mo agoMerck signs $2.13 billion deal for SciBrunch's SPR2015 inhibitor
Merck acquires global rights to SPR2015, an oral KRAS G12D inhibitor, from SciBrunch. Upfront payment of $400 million recorded as pre-tax charge in Q3 2026. Total potential deal value reaches $2.13 billion including milestone payments. SPR2015 shows antitumor efficacy in preclinical models targeting mutant KRAS.
1mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $1,373.70 | +6.63% | $12,93,142.11M | 39.43 | |
| $275.20 | +1.53% | $6,62,491.71M | 31.06 | |
| $290.79 | +1.68% | $5,13,859.95M | 72.17 | |
| $161.10 | +3.22% | $3,27,809.50M | 23.23 | |
| $174.40 | +2.88% | $2,70,478.36M | 24.32 | |
| $460.73 | +1.97% | $2,49,085.38M | 26.86 | |
| $165.61 | +4.03% | $2,05,348.95M | - | |
| $29.95 | +1.70% | $1,70,705.24M | 36.79 | |
| $39.14 | +2.22% | $1,32,689.61M | 11.15 | |
| $61.39 | +1.35% | $1,25,402.27M | 14.67 | |
| $48.68 | -0.12% | $1,05,059.03M | 16.01 | |
| $43.13 | +2.11% | $1,04,182.50M | 23.63 |
An investment of $100 made 5 years ago in Merck & Co is now worth
$ 170.06
giving a profit of
$ 70.06 (70.06%)
Note: Past profits do not guarantee future returns.
